Answers are grounded in this paper and cite their sources.
Purpose Systemic lupus erythematosus (SLE) often presents with significant phenotypic overlap with other autoimmune conditions, complicating accurate differential diagnosis. To address this clinical challenge, we developed a computational architecture integrating immunoinflammatory biomarkers to facilitate objective diagnostic risk stratification for SLE among symptomatic patients. Methods A retrospective observational framework was adopted, encompassing 1,950 individuals partitioned into 1,000 definitive lupus cases and 950 symptomatic non-SLE controls. To extract core distinguishing indicators, a bipartite screening methodology merging LASSO techniques with Boruta random forest evaluations was deployed. This isolated seven essential molecular targets: antinuclear antibodies (ANA), C-reactive protein (CRP), interferon-gamma inducible protein 10 (IP-10), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), B-cell activating factor (BAFF), and anti-double-stranded DNA (anti-dsDNA). Among seven rigorously evaluated machine learning algorithms, logistic regression was selected as the primary diagnostic model due to its optimal balance of predictive robustness and interpretability in the internal validation cohort. This algorithm was translated into a graphical scoring index. Furthermore, to address potential incorporation bias, an autoantibody-independent cytokine-only panel was evaluated. Results During internal validation cohort verification, the integrated logistic regression model achieved 81.0% specificity, 83.0% sensitivity, 82.0% accuracy, and an area under the receiver operating characteristic curve (AUC) of 0.851, outperforming individual predictors ( P < 0.001) and complex algorithms prone to structural overfitting. Crucially, the autoantibody-independent panel (comprising BAFF, IL-6, TNF-α, IP-10, and CRP) demonstrated robust independent diagnostic efficacy, achieving an AUC of 0.820 in the internal validation cohort and substantially outperforming the conventional ANA and anti-dsDNA baseline (AUC = 0.765). Decision curve analysis confirmed that the integrated multifactorial tool consistently delivered greater net clinical benefit across extensive threshold probabilities compared to standard diagnostic baselines. Conclusions This investigation delivers a promising computational strategy to assist in distinguishing SLE from phenotypically overlapping disorders. The developed graphical tool serves as a potential decision-support framework for objective risk stratification. Furthermore, prospective multicenter external validation will further enhance its generalizability and clinical utility.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: